David L. DeRemer

1.6k total citations
64 papers, 1.1k citations indexed

About

David L. DeRemer is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, David L. DeRemer has authored 64 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 15 papers in Hematology and 13 papers in Molecular Biology. Recurrent topics in David L. DeRemer's work include Chronic Lymphocytic Leukemia Research (8 papers), Pancreatic and Hepatic Oncology Research (8 papers) and Multiple Myeloma Research and Treatments (5 papers). David L. DeRemer is often cited by papers focused on Chronic Lymphocytic Leukemia Research (8 papers), Pancreatic and Hepatic Oncology Research (8 papers) and Multiple Myeloma Research and Treatments (5 papers). David L. DeRemer collaborates with scholars based in United States, Georgia and Canada. David L. DeRemer's co-authors include Celalettin Üstün, Payaningal R. Somanath, Kavita Natarajan, Belal Al‐Husein, Maha Abdalla, Cem Akin, Amber B. Clemmons, Farrukh T. Awan, Susan C. Fagan and Azza B. El‐Remessy and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

David L. DeRemer

57 papers receiving 1.1k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
David L. DeRemer	310	295	258	139	129	64	1.1k
Jennifer H. Foster	429 1.4×	262 0.9×	101 0.4×	81 0.6×	113 0.9×	63	1.1k
Michael P. Chu	308 1.0×	570 1.9×	239 0.9×	168 1.2×	246 1.9×	66	1.2k
Jing Cui	412 1.3×	237 0.8×	100 0.4×	75 0.5×	188 1.5×	70	1.2k
Chih‐Fen Huang	539 1.7×	204 0.7×	577 2.2×	66 0.5×	121 0.9×	55	1.3k
Charlotte van Kesteren	256 0.8×	375 1.3×	747 2.9×	381 2.7×	224 1.7×	45	1.6k
Virginia E. Kwitkowski	484 1.6×	423 1.4×	119 0.5×	81 0.6×	264 2.0×	18	1.2k
Yuping Gong	669 2.2×	231 0.8×	268 1.0×	90 0.6×	64 0.5×	83	1.2k
Marie‐Hélène Schlageter	342 1.1×	421 1.4×	321 1.2×	93 0.7×	106 0.8×	39	1.4k
F. Ries	330 1.1×	622 2.1×	173 0.7×	189 1.4×	325 2.5×	70	1.7k
Michaëla Semeraro	224 0.7×	319 1.1×	94 0.4×	276 2.0×	117 0.9×	34	989

Countries citing papers authored by David L. DeRemer

Since Specialization

Citations

This map shows the geographic impact of David L. DeRemer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David L. DeRemer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David L. DeRemer more than expected).

Fields of papers citing papers by David L. DeRemer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David L. DeRemer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David L. DeRemer. The network helps show where David L. DeRemer may publish in the future.

Co-authorship network of co-authors of David L. DeRemer

This figure shows the co-authorship network connecting the top 25 collaborators of David L. DeRemer. A scholar is included among the top collaborators of David L. DeRemer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David L. DeRemer. David L. DeRemer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cicali, Emily J., Elizabeth M. Eddy, Yan Gong, et al.. (2024). Implementation of a pharmacogenetic panel‐based test for pharmacotherapy‐based supportive care in an adult oncology clinic. Clinical and Translational Science. 17(7). e13890–e13890. 1 indexed citations

George, Thomas J., Ji‐Hyun Lee, David L. DeRemer, et al.. (2024). Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms. JCO Precision Oncology. 8(8). e2400406–e2400406. 6 indexed citations

George, Thomas J., Ibrahim Nassour, İlyas Şahin, et al.. (2024). Results of a phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study).. Journal of Clinical Oncology. 42(3_suppl). 655–655. 1 indexed citations

Allen, John M., Yi Guo, Jiang Bian, et al.. (2023). Unraveling Racial Disparities in Supportive Care Medication Use among End-of-Life Pancreatic Cancer Patients: Focus on Pain Management and Psychiatric Therapies. Cancer Epidemiology Biomarkers & Prevention. 32(12). 1675–1682. 3 indexed citations

DeRemer, David L., Avirup Guha, Faraz S. Ahmad, et al.. (2023). Racial and Ethnic Differences in Cardiac Surveillance Evaluation of Patients Treated With Anthracycline‐Based Chemotherapy. Journal of the American Heart Association. 12(10). e027981–e027981. 6 indexed citations

Bruno, Katelyn A., Walter G. O’Dell, Meghan C. Ferrall‐Fairbanks, et al.. (2023). Research summary of poster presentations at the 2023 Florida cardio-oncology symposium. SHILAP Revista de lepidopterología. 37. 100348–100348.

DeRemer, David L., Edward Agyare, John M. Allen, et al.. (2023). Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans. Journal of the National Medical Association. 115(2). 164–174. 3 indexed citations

Ramnaraign, Brian Hemendra, et al.. (2021). Immunotherapy Management in Special Cancer Patient Populations. JCO Oncology Practice. 17(5). 240–245. 9 indexed citations

Chen, Ziyan, et al.. (2021). Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research. 21(5). 923–941. 2 indexed citations

10.

Waheed, Nida, Michael G. Fradley, David L. DeRemer, et al.. (2021). Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center. Cardio-Oncology. 7(1). 10–10. 29 indexed citations

11.

DeRemer, David L., et al.. (2019). Immune-mediated adverse events following influenza vaccine in cancer patients receiving immune checkpoint inhibitors. Journal of Oncology Pharmacy Practice. 26(3). 647–654. 17 indexed citations

12.

Phillips, Beth Bryles, et al.. (2019). Pharmacy Student Performance in a Capstone Course Utilizing the Pharmacists’ Patient Care Process. American Journal of Pharmaceutical Education. 83(8). 7357–7357. 28 indexed citations

13.

Clemmons, Amber B., et al.. (2018). Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial. Biology of Blood and Marrow Transplantation. 24(10). 2065–2071. 32 indexed citations

14.

Deal, Eli N., Paul M. Stranges, Whitney D. Maxwell, et al.. (2016). The Importance of Research and Scholarly Activity in Pharmacy Training. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 36(12). e200–e205. 49 indexed citations

15.

Mangaonkar, Abhishek A., Hongyan Xu, Mohsin Jamal, et al.. (2016). Prognostic value of complete remission with superior platelet counts in acute myeloid leukemia. The Journal of Community and Supportive Oncology. 14(2). 66–71. 3 indexed citations

16.

Awan, Farrukh T., Samith T. Kochuparambil, Aaron Cumpston, et al.. (2013). Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. Bone Marrow Transplantation. 48(10). 1279–1284. 41 indexed citations

17.

Awan, Farrukh T., Samith T. Kochuparambil, David L. DeRemer, et al.. (2012). Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization. Journal of Oncology. 2012. 1–5. 11 indexed citations

18.

Hamadani, Mehdi, Samith T. Kochuparambil, Aaron Cumpston, et al.. (2012). Intermediate-Dose versus Low-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Therapies. Biology of Blood and Marrow Transplantation. 18(7). 1128–1135. 55 indexed citations

19.

DeRemer, David L., et al.. (2011). Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia. Cancer Management and Research. 3. 65–65. 7 indexed citations

20.

DeRemer, David L., Celalettin Üstün, & Kavita Natarajan. (2008). Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clinical Therapeutics. 30(11). 1956–1975. 138 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact